Top Tweets for #Hughes4Chair
@Mike182035 @TVR5AVCT @hughesy0707 Mike what's your view on #Hughes4chair now considering Richard has practically sorted the CLN, backed the company with massive share purchases, massively raised the SP, brought in ii's in a series of great fundraises & basically saved the company from financial disaster? #AVCT
We look forward to Richard Hughes being formally appointed Chair of #AVCT on Monday.
#Hughes4Chair ✅
As a shareholder base representing 9.19% of #AVCT’s TVR, we are delighted to see a board member finally grappling with the thorny issues and finding solutions.
Richard has @TVR5AVCT’s full support.
#Hughes4Chair
A necessary piece of housekeeping ahead of a transformative 12 months. Not the last piece of dead weight that needs removing however. #AVCT #hughes4chair
TVR5 welcomes the removal of Panmure as broker to #AVCT.
pre|CISION’s utility is far too wide to accurately quantify the platform’s value at this nascent stage.
Failure by Panmure to ascribe any value to said platform was demonstrative of indifference and/or incompetence.
@RAH00084 @avacta Excellent summary; all the more reason we need Richard Hughes in the Chair #AVCT #Hughes4Chair #hughesy0707
It's the first time I've genuinely felt like we have someone at Avacta looking out for shareholders.
@MylesMcNulty We need someone who delivers in the chair before the pharma games kick off to avoid a derisory outcome here. The tech sells. #Hughes4Chair
The biggest 6 months in the Avacta story? Certainly getting to the sharp end of the pencil. Time for a strengthening of the board to support the CEO. #avct @hughesy0707 #Hughes4Chair
#AVCT has a jam packed Q4 25 - Q1 26:
✍️ pre|CISION to another warhead
🇩🇪 Tap @ #ESMO25
🩻 SGC data
☢️ AVA6000 long term safety data
🩻 TNBC data
🪑#Hughes4Chair
✍️ AVA6000 (multiple indications)
📑 AVA6103 IND filed
🧬 AVA6103 enters human
3️⃣ Selection of Gen3 drug
#AVCT looking ready to move into second gear.
Tap with a 45 minute slot on AVA6000 sat on four years of data and a clean safety profile courtesy of a proven peptide.
Have a look at Tap’s twitter followers if you want an idea as to the reach this MD has.
Here we go!
#AVCT looking ready to move into second gear.
Tap with a 45 minute slot on AVA6000 sat on four years of data and a clean safety profile courtesy of a proven peptide.
Have a look at Tap’s twitter followers if you want an idea as to the reach this MD has.
Here we go!
#AVCT has a jam packed Q4 25 - Q1 26:
✍️ pre|CISION to another warhead
🇩🇪 Tap @ #ESMO25
🩻 SGC data
☢️ AVA6000 long term safety data
🩻 TNBC data
🪑#Hughes4Chair
✍️ AVA6000 (multiple indications)
📑 AVA6103 IND filed
🧬 AVA6103 enters human
3️⃣ Selection of Gen3 drug
#AVCT : Reading the Website Signals
1. Ava7100 page shifts from outline to disclosure ready detail.
The pipeline now shows Ava7100 as an Affimer-based FAP-cleavable conjugate, with candidate selection guided for H2-2025 and an IND targeted for H2-2026. The same page confirms the construct with a DAR = 5 (DAR = drug-to-antibody ratio, i.e. the average number of payload molecules attached per targeting scaffold, a key determinant of potency and safety). Some analyst reports (e.g https://t.co/D7FbvuwooE ) also reference a DAR 4–5 design.
This likely means pharmacology and manufacturability questions have already been worked through to a point where disclosure structure has been locked, and that a nomination announcement is most probably in late stage preparation.
2. Indication narrowing : internal data is driving trial blueprints.
Ava7100 has shifted from broad “cancers” to specific tumour types (HNSCC, NSCLC, CRC). Companies don’t narrow disease wording unless translational data consistently points to those areas. This likely reflects preclinical evidence crossing the threshold needed to inform draft protocols. It also most probably means biomarker thresholds or patient selection criteria are already being shaped in regulatory discussions.
3. 6103 and 6000 are being choreographed to reinforce 7100.
The site confirms 6103 is in INDenabling, with IND planned for Q4-2025/Q1-2026 and Phase 1 start in Q1-2026. Meanwhile, 6000 expansion data are expected in late-2025 (salivary gland) and H1-2026 (TNBC) https://t.co/6XLjAqEUJz
Lining these dates against the 7100 nomination window suggests deliberate timing: it is most likely designed to present efficacy (6000), diversification (6103), and a next gen Affimer construct (7100) in close succession. Again, platform level choreography rather than isolated milestones.
4. The presentation of the site now carries the fingerprints of preparation for external review.
Diagnostics have been stripped back, pipeline graphics simplified, and program language made uniform, with BD contact details clearly highlighted (from the Avacta pipeline webpage: “To explore how we can work together, please contact our Chief Business Officer.”). Those of us at the AGM also heard direct reference to ongoing “talks”. The Annual Report 2025 explicitly states they are seeking a partner for Ava6000 and will evaluate licensing opportunities after data. The timing, set to coincide with upcoming disclosures, makes it very likely the company is shaping its narrative for partner ready assessment.
5. Reading the behaviour: a chain of announcements is being set up.
The combination of new Ava7100 details, greater precision in cancer targets, Ava6000 expansion timelines, and streamlined messaging points to a coordinated build up. The company is most probably preparing to drop several updates in close succession (nomination, expansion data, and IND filing) to present the platform as both mature and broad within a defined window.
Intelligent Take:
#AVCT is very likely syncing its external messaging with internal progress, the hallmarks of a biotech on the verge of shifting gears. These edits are the preconditions of disclosure. When timelines, indications, and partner facing language all converge, it usually means the next wave of data is already being arranged into a narrative precise enough to withstand outside scrutiny and, most probably, external negotiation already in progress.
Last Seen Hashtags on Sotwe
osmaniyepasif
Seen from Turkey
sofiathefirstroyalmagic
Seen from United States
Prolapse
Seen from France
butimissyouall
Seen from United States
sobrina
Seen from Mexico
diyarbakırtravesti
Seen from Turkey
momson()*** Filter:videos
Seen from Saudi Arabia
mlbbnsfw
Seen from Indonesia
alanyaescort
Seen from Turkey
アズマコーダイがいる日常
Seen from United Kingdom
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.4M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.1M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.5M followers
Virat Kohli
@imvkohli
70.6M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.1M followers
Neymar Jr
@neymarjr
63.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.2M followers
X
@x
60.8M followers